Skip to main content
. 2008 Jan 29;5(1):e26. doi: 10.1371/journal.pmed.0050026

Figure 2. HSCT Restores Anti-Mycobacterial Immunity in Ifngr1−/− Mice.

Figure 2

(A) Ifngr1−/− and Ifngr+/+ mice (five animals per group) expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngr+/+ mice expressing the Ly5.1 marker, after intense irradiation (1,200 rads). Chimerism, assessed by determining the surface expression of Ly5.1 and Ly5.2 on lymphocytes, and peripheral reconstitution, assessed by determining the surface expression of TCRαβ and B220 markers on lymphocytes, were analysed by flow cytometry nine weeks after HSCT treatment.

(B) Ifngr1−/− and Ifngr+/+ mice were subjected to HSCT with bone marrow from Ifngr1−/− or Ifngr+/+ mice. HSCT-treated mice were then infected with BCG and bacterial loads were determined 45 d later (five animals per group).

(C) Ifngr1−/− and Ifngr+/+ mice expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngr+/+ mice expressing the Ly5.1 marker, after mild irradiation (550 rads). Chimerism and peripheral reconstitution were analysed by flow cytometry nine weeks after HSCT treatment.

(D) Ifngr1−/− and Ifngr+/+ mice were subjected to HSCT with bone marrow from Ifngr+/+ mice after intense or mild irradiation, infected with BCG and bacterial load was determined 45 d later.